FGFR4 and cancer: There have also been many studies that failed to observe any significant contribution of the FGFR4 Gly388Arg SNP to the clinicopathological parameters or prognosis in patients with cancer (13, 14, 16, 17, 21, 23, 26, 27, 35, 47–65).